A Study To Assess Biomarkers Of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH)
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 20-012424
NCT ID: NCT04467489
About this study
The purpose of this study is to develop prognostic and diagnostic blood tests for symptomatic brain hemorrhage in patients diagnosed with cavernous angiomas, a critical clinical challenge in a disease affecting more than a million Americans. We further examine whether blood biomarkers can replace or enhance the accuracy of advanced imaging in association with lesional bleeding. The project tests a novel integrational approach of biomarker development in a mechanistically defined cerebrovascular disease, with a clinically relevant context of use.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Clinical diagnosis of CA.
- Age 18 or older.
- Ssolitary or multiple.
- Familial or sporadic.
- With or without prior symptoms.
Exclusion Criteria:
- Prior excision of a solitary CA lesion.
- Prior stereotactic radiosurgery or any brain irradiation.
- Spinal cavernoma without brain lesion.
- Other brain pathology unrelated to CA (demyelinating disease, brain tumor).
- Seizures or stroke unrelated to CA in the prior year.
- Current pregnancy or within 6 months postpartum.
- Reluctance to undergo venipuncture or donate blood specimen, or be called for clinical follow-up for up to one year.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Rochester, Minn.
Mayo Clinic principal investigator Kelly Flemming, M.D. |
Closed for enrollment |
|
More information
Publications
Publications are currently not available